During the corresponding time, Journey Medical Corp recorded a revenue increase by 23.33 % year on year, sequentially revenue grew by 15.97 %. While revenue at the Journey Medical Corp's corporate clients
Journey Medical's Comment on Sales, Marketing and Customers
The company operates in the dermatology market, primarily serving medical dermatology providers and their patients. Its field sales force covers more than 80% of dermatologists in the top 50 U.S. metropolitan statistical areas and over 70% of the overall dermatology prescribing market. Products are distributed through a specialized network of over 600 specialty pharmacies and wholesalers, with limited reliance on traditional national wholesalers. The company targets dermatology providers by utilizing experienced sales personnel to establish relationships within the dermatology community. Its business development strategy focuses on synergistic acquisitions and transformative assets to enhance scale and capabilities. Customers and markets referenced in filings include Bausch Health Pharmaceuticals, Inc., Medicis Pharmaceutical, Inc., and Valeant Pharmaceuticals, Inc.
Revolutionizing Rosacea Treatment: Journey Medical Corporation s Emrosi Receives FDA ApprovalIn a significant advancement for dermatological therapeutics, Journey Medical Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of rosacea. This newly approved medication marks a pivotal step forward in managing a condition that affects millions of individuals globally. Emrosi represents a novel therapeutic option offering improved management over existing treatments and providing new hope for patients suffering from this chronic inflammatory skin condition. Understanding Rosacea and Treatment ...
Journey Medical Corporation recently announced the presentation of data from a Phase 1 clinical trial assessing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This significant milestone was shared at the 2024 American Academy of Dermatology (AAD) Annual Meeting. The company successfully achieved all three primary s of the trial, with subjects completing a 16-week treatment period without experiencing any significant safety issues.Factual Interpretation:The Phase 1 clinical trial aimed to evaluate the impact of DFD-29, a modified release capsule containing 40 mg of Minocycline Hydrochloride, on the microbial flora of healthy adults. The trial results were presented at ...
Journey Medical’s Comment on Sales, Marketing and Customers
The company operates in the dermatology market, primarily serving medical dermatology providers and their patients. Its field sales force covers more than 80% of dermatologists in the top 50 U.S. metropolitan statistical areas and over 70% of the overall dermatology prescribing market. Products are distributed through a specialized network of over 600 specialty pharmacies and wholesalers, with limited reliance on traditional national wholesalers. The company targets dermatology providers by utilizing experienced sales personnel to establish relationships within the dermatology community. Its business development strategy focuses on synergistic acquisitions and transformative assets to enhance scale and capabilities. Customers and markets referenced in filings include Bausch Health Pharmaceuticals, Inc., Medicis Pharmaceutical, Inc., and Valeant Pharmaceuticals, Inc.
Sources:
Journey Medical Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Journey Medical Corp’s corporate clients.
For your research, we’ve provided 9 tables on Journey Medical Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
77.4 %